Ying‐Chun Shen

4.1k total citations
90 papers, 2.1k citations indexed

About

Ying‐Chun Shen is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ying‐Chun Shen has authored 90 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 28 papers in Hepatology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ying‐Chun Shen's work include Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Cancer Mechanisms and Therapy (14 papers). Ying‐Chun Shen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Cancer Mechanisms and Therapy (14 papers). Ying‐Chun Shen collaborates with scholars based in Taiwan, United States and China. Ying‐Chun Shen's co-authors include Ann‐Lii Cheng, Chiun Hsu, Chih‐Hung Hsu, Yu‐Yun Shao, Zhong‐Zhe Lin, Fu‐Chang Hu, Чиа-Чи Ченг, Chee‐Jen Chang, Da‐Liang Ou and Chang-Fang Chiu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Ying‐Chun Shen

85 papers receiving 2.1k citations

Peers

Countries citing papers authored by Ying‐Chun Shen

Since Specialization

Citations

This map shows the geographic impact of Ying‐Chun Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying‐Chun Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying‐Chun Shen more than expected).

Fields of papers citing papers by Ying‐Chun Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying‐Chun Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying‐Chun Shen. The network helps show where Ying‐Chun Shen may publish in the future.

Co-authorship network of co-authors of Ying‐Chun Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Ying‐Chun Shen. A scholar is included among the top collaborators of Ying‐Chun Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying‐Chun Shen. Ying‐Chun Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models 2025 ·Journal for ImmunoTherapy of Cancer ·Ying‐Chun Shen, (unknown), (unknown), (unknown), Ming‐Feng Wei, Da‐Liang Ou, Chia‐Lang Hsu, Ann‐Lii Cheng	2
2	Matrine Reduces Intraocular Pressure in Corticosteroid-Induced Ocular Hypertensive Mouse Eyes 2025 ·Investigative Ophthalmology & Visual Science ·Qí Zhāng, Zhiquan Liu, (unknown), (unknown), (unknown), Ke Ning, (unknown), Ying‐Chun Shen, Paloma B. Liton, Yang Sun	0
3	Different allergen-induced asthma and anaphylaxis show distinctive IgE pathway dependence 2024 ·SHILAP Revista de lepidopterología ·Ying‐Chun Shen, Xuan Yuan, Shaobing Xie, Wei Tu, Peisong Gao	1
4	Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression 2024 ·Liver Cancer ·Tsung‐Hao Liu, San‐Chi Chen, Kun‐Ming Rau, Li‐Chun Lu, (unknown), Yung‐Yeh Su, Wei Teng, Shiue‐Wei Lai, (unknown), (unknown), Pei‐Chang Lee, (unknown), Chien‐Hung Chen, Chih‐Hung Hsu, Shi‐Ming Lin, Yi‐Hsiang Huang, Li‐Tzong Chen, Ann‐Lii Cheng, Ying‐Chun Shen	7
5	Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis 2023 ·Cancer Medicine ·(unknown), Ching‐Hung Lin, I‐Chun Chen, Ying‐Chun Shen, Dwan‐Ying Chang, Tom Wei‐Wu Chen, Shu‐Min Huang, Fu‐Chang Hu, Yen‐Shen Lu	1
6	Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors 2023 ·Oncology ·(unknown), Bin-Chi Liao, Wei‐Hsun Hsu, Ching‐Yao Yang, Yen‐Ting Lin, Shang‐Gin Wu, Tzu-Hsiu Tsai, Kuan‐Yu Chen, Chao‐Chi Ho, Wei‐Yu Liao, Jin‐Yuan Shih, Chong‐Jen Yu, James C. Yang, Ann‐Lii Cheng, Ying‐Chun Shen	5
7	Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation 2022 ·JCI Insight ·Xiaoyan Luo, Jingsi Chen, Huan Yang, Xinyue Hu, Martin P. Alphonse, Ying‐Chun Shen, Yuko Kawakami, Xiaoying Zhou, Wei Tu, Toshiaki Kawakami, Mei Wan, Nathan K. Archer, Hua Wang, Peisong Gao	23
8	Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape 2022 ·Journal of the Formosan Medical Association ·Tsung‐Hao Liu, Ying‐Chun Shen, Ann‐Lii Cheng	3
9	P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 2021 ·Annals of Oncology ·Bruno Sangro, Kazushi Numata, Yi‐Hsiang Huang, Carlos Gómez-Martín, Atsushi Hiraoka, Michihisa Moriguchi, Ying‐Chun Shen, Andrea Horváth, William F. Feely, Tina C. Young, Jaclyn Neely, Masatoshi Kudo	11
10	Epithelial Aryl Hydrocarbon Receptor Protects From Mucus Production by Inhibiting ROS-Triggered NLRP3 Inflammasome in Asthma 2021 ·Frontiers in Immunology ·Xinyue Hu, Ying‐Chun Shen, Yilin Zhao, Ji Wang, Xin Zhang, (unknown), (unknown), (unknown), Peisong Gao	37
11	MCC950 Ameliorates Acute Liver Injury Through Modulating Macrophage Polarization and Myeloid-Derived Suppressor Cells Function 2021 ·Frontiers in Medicine ·Wei Yan, Ying‐Chun Shen, (unknown), Ling Lü, Qian Zhang	11
12	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy 2020 ·The Oncologist ·Zhong‐Zhe Lin, Bang‐Bin Chen, Yi‐Ping Hung, (unknown), Ying‐Chun Shen, Yu‐Yun Shao, Chih‐Hung Hsu, Ann‐Lii Cheng, Rheun‐Chuan Lee, Yee Chao, Chiun Hsu	17
13	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma 2019 ·Journal of Hepatology ·Ying‐Chun Shen, Chia‐Lang Hsu, Yung‐Ming Jeng, Ming‐Chih Ho, Cheng‐Maw Ho, (unknown), Chia‐Yu Yeh, (unknown), Rey‐Heng Hu, Ann‐Lii Cheng	42
14	Histological characteristics of induced membranes in subcutaneous, intramuscular sites and bone defect 2013 ·Orthopaedics & Traumatology Surgery & Research ·(unknown), (unknown), Peng Shang, Ying‐Chun Shen, (unknown), Lei Peng, (unknown)	48
15	Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma 2011 ·Oncology ·Ann‐Lii Cheng, Ying‐Chun Shen, Andrew X. Zhu	43
16	Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells 2010 ·Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Sung‐Liang Yu, Kuen‐Feng Chen, (unknown), (unknown), Wen-Chi Feng, (unknown), Liang‐In Lin, Chiun Hsu, Ann‐Lii Cheng	68
17	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma 2010 ·Journal of Hepatology ·Chih‐Hung Hsu, Ying‐Chun Shen, Zhong‐Zhe Lin, Pei‐Jer Chen, Yu‐Yun Shao, (unknown), Chiun Hsu, Ann‐Lii Cheng	104
18	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma 2009 ·Clinical Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Ja‐Der Liang, Jun‐Yang Liou, Sung‐Liang Yu, (unknown), Dasheng Wang, Yen‐Shen Lu, Chiun Hsu, Ann‐Lii Cheng	36
19	Potential synergistic anti-tumor effects between sorafenib and the MEK inhibitor CI1040 in hepatocellular carcinoma (HCC) 2008 ·Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Sung‐Liang Yu, Wei-Chung Allen Lee, (unknown), Chiun Hsu, Ann‐Lii Cheng	1
20	Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines 2004 ·British Journal of Cancer ·Ying‐Chun Shen, Chiun Hsu, J-Y Chen, Ann‐Lii Cheng	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact